Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology October 30, 2016 Reji Thomas, Mesut Çetin, Glen B. Baker et al. 6 citations - DOI: 10.5455/bcp.20161027122045 (opens in new tab)